7/24/2014 11:14:32 AM
Gilead Sciences, Inc. Announces Second Quarter 2014 Financial Results
- Product Sales of $6.41 billion -
- Sovaldi Sales of $3.48 billion -
- Non-GAAP EPS of $2.36 per share -
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended June 30, 2014. Total revenues for the second quarter of 2014 increased to $6.53 billion compared to $2.77 billion for the second quarter of 2013. Product sales for the second quarter of 2014 increased to $6.41 billion compared to $2.66 billion for the second quarter of 2013.
“During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since December’s launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical community’s recognition of the benefits of this product,” said John C. Martin, PhD, Gilead’s Chairman and Chief Executive Officer. “We look forward to making Sovaldi available in additional countries.”
For full article, please click here.
Help employers find you! Check out all the jobs and post your resume.
comments powered by